Latest

09:17
【EB SECURITIES(06178.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.23 billion, YoY increase of 32.45%】NewTimeSpace News: August 19, 2026, EB SECURITIES(06178.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 8.73 billion, increased by 16.64% YoY.
Tag： EB SECURITIES06178.HKprofit growth
09:15
【ARCHOSAUR GAMES(09990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 68.52 million, loss widened by 484.11% YoY】NewTimeSpace News: August 19, 2026, ARCHOSAUR GAMES(09990.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 608.61 million, decreased by 4.06% YoY.
Tag： ARCHOSAUR GAMES09990.HKLoss widens
09:10
【CHENQI TECH(09680.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 68.49 million, loss narrowed by 45.17% YoY】NewTimeSpace News: August 19, 2026, CHENQI TECH(09680.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 4.04 billion, increased by 140.7% YoY.
Tag： CHENQI TECH09680.HKloss narrowed
09:09
【ASCENTAGE(06855.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 816.69 million, loss widened by 38.24% YoY】NewTimeSpace News: August 20, 2026, ASCENTAGE(06855.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 302.21 million, increased by 29.32% YoY.
Tag： ASCENTAGE06855.HKLoss widens
09:07
【QYUNS-B(02509.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 203.32 million, turned profitable from a loss YoY】NewTimeSpace News: August 19, 2026, QYUNS-B(02509.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 424.06 million, increased by 105.37% YoY.
Tag： QYUNS-B02509.HKturned profitable from loss
09:05
【SICC(02631.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 58.62 million, turned into a loss from a profit YoY】August 19, 2026, SICC(02631.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 913.65 million, increased by 15.1% YoY
Tag： SICC02631.HKturned into a loss from a profit
09:02
【XTALPI(02228.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 251.9 million, turned into a loss from a profit YoY】NewTimeSpace News: August 19, 2026, XTALPI(02228.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 393.63 million, decreased by 23.87% YoY.
Tag： XTALPI02228.HKturned into a loss from a profit
09:02
【DTECH(01377.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 679.13 million, YoY increase of 325.12%】NewTimeSpace News: August 19, 2026, DTECH(01377.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.83 billion, increased by 104.84% YoY.
Tag： Dtech01377.HKprofit growth
09:02
【SISRAM MED(01696.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of USD 1.16 million, turned into a loss from a profit YoY】NewTimeSpace News: August 19, 2026, SISRAM MED(01696.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 171.42 million, increased by 3.59% YoY.
Tag： SISRAM MED01696.HKturned into a loss from a profit
09:02
【RECBIO-B(02179.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 211.82 million, loss narrowed by 37.82% YoY】NewTimeSpace News: August 19, 2026, RECBIO-B(02179.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 47 thousand, decreased by 99.57% YoY.
Tag： RECBIO-B02179.HKloss narrowed
09:02
【CHINA BLUECHEM(03983.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 507.45 million, YoY decrease of 20.78%】NewTimeSpace News: August 19, 2026, CHINA BLUECHEM(03983.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.62 billion, decreased by 3.95% YoY.
Tag： CHINA BLUECHEM03983.HKProfit declined
09:02
【CH TIANBAO GP(01427.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 64.73 million, loss widened by 73.56% YoY】NewTimeSpace News: August 19, 2026, CH TIANBAO GP(01427.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 368.68 million, decreased by 55.44% YoY.
Tag： CH TIANBAO GP01427.HKLoss widens
09:02
【SOFTCARE(02698.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 75.82 million, YoY increase of 46%】NewTimeSpace News: August 19, 2026, SOFTCARE(02698.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 332.75 million, increased by 30.68% YoY.
Tag： SOFTCARE02698.HKprofit growth
09:02
【AIA(01299.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 4.29 billion, YoY increase of 69.46%】NewTimeSpace News: August 20, 2026, AIA(01299.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 11.69 billion, increased by 11.69% YoY.
Tag： AIA01299.HKprofit
09:02
【JIUYUAN GENE(02566.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 91.27 million, YoY increase of 1.21%】NewTimeSpace News: August 19, 2026, JIUYUAN GENE(02566.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 630.95 million, decreased by 1.23% YoY.
Tag： JIUYUAN GENE02566.HKprofit
09:02
【CMOC(03993.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 16.15 billion, YoY increase of 86.27%】NewTimeSpace News: August 19, 2026, CMOC(03993.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 135.32 billion, increased by 42.78% YoY.
Tag： CMOC03993.HKprofit growth
08:43
【TINCI (002709.SZ): H-share issuance obtains CSRC filing, plans to issue up to 412,760,200 H-shares for Hong Kong listing】NewTimeSpace News: On 20 August 2026, TINCI (002709.SZ) announced that its H-share issuance has obtained the CSRC filing for overseas offering and listing, planning to issue up to 412,760,200 overseas listed ordinary shares for listing on the Hong Kong Stock Exchange; the filing notice is valid for 12 months, and updated filing materials are required if the listing is not completed within that period.
Tag： TINCI002709.SZNotice of Overseas Listing RegistrationIPO
08:31
【SKG Health Technologies: refiles for Hong Kong listing on 19 August, CITIC Securities International as sole sponsor; No.1 in China's smart soothing wearable device market】NewTimeSpace News: On 19 August 2026, SKG Health Technologies Co., Ltd. refiled for a Hong Kong listing, with CITIC Securities International as the sole sponsor; the Company is a health technology company ranking first among domestic participants in China's smart soothing wearable device industry by 2025 GMV with a market share of 21.6%, holding 1,554 registered patents globally.
Tag： SKGIPOfile a listing application
08:20
【LEADS BIOLABS-B (09887.HK): Phase II study abstract of Vimx (opasumivimab) as first-line NSCLC therapy published on WCLC website】NewTimeSpace News: On 20 August 2026, LEADS BIOLABS-B (09887.HK) voluntarily announced that the Phase II study abstract of Vimx™ (a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line NSCLC therapy has been published on the WCLC website, with an ORR of 65.0% and DCR of 95.0% in 60 evaluable patients and an ORR of 77.4% in the squamous subgroup; updated data from follow-up exceeding seven months will be presented orally at WCLC on 14 September.
Tag： LEADS BIOLABS-B09887.HKClinical Progress
08:18
【GENFLEET-B (02595.HK): two first-in-class pancreatic cancer combination therapies of GFH375 advance to Phase II studies】NewTimeSpace News: On 20 August 2026, GENFLEET-B (02595.HK) voluntarily announced that a three-arm parallel-controlled Phase II study of oral KRAS G12D inhibitor GFH375 has been initiated for patients with previously treated KRAS G12D-mutated pancreatic cancer, including two first-in-class combination regimens (with cachexia bispecific GFS202A and pan-RAS inhibitor GFH276); GFH375 previously obtained breakthrough therapy designation in China and US FDA fast track designation.
Tag： GENFLEET-B02595.HKClinical Trial
Previous1..5556 575859..490     490 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments